Carlos A Molina Selected Research

Time-to-Treatment

9/2014	Impact of time to treatment on tissue-type plasminogen activator-induced recanalization in acute ischemic stroke.
4/2014	Baseline National Institutes of Health stroke scale-adjusted time window for intravenous tissue-type plasminogen activator in acute ischemic stroke.
4/2011	Bridging intravenous-intra-arterial rescue strategy increases recanalization and the likelihood of a good outcome in nonresponder intravenous tissue plasminogen activator-treated patients: a case-control study.
8/2009	Treatment and outcomes of acute basilar artery occlusion in the Basilar Artery International Cooperation Study (BASICS): a prospective registry study.
10/2008	Do bubble characteristics affect recanalization in stroke patients treated with microbubble-enhanced sonothrombolysis?
1/2008	Geographic differences in acute stroke care in Catalunya: impact of a regional interhospital network.
11/2007	Timing of recanalization after microbubble-enhanced intravenous thrombolysis in basilar artery occlusion.
3/2007	Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke.
2/2006	Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator.
9/2004	Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Carlos A Molina Research Topics

Disease

118	Stroke (Strokes) 12/2022 - 06/2002
63	Ischemic Stroke 12/2022 - 04/2003
19	Transient Ischemic Attack 01/2022 - 10/2003
17	Hemorrhage 01/2022 - 02/2003
17	Infarction (Infarctions) 01/2021 - 06/2002
12	Cerebral Hemorrhage 01/2018 - 07/2003
9	Embolic Stroke 01/2022 - 02/2004
9	Intracranial Hemorrhages (Intracranial Hemorrhage) 01/2021 - 09/2004
9	Myocardial Infarction 10/2019 - 06/2008
8	Brain Ischemia (Cerebral Ischemia) 10/2019 - 02/2003
6	Pathologic Constriction (Stenosis) 12/2020 - 01/2005
5	Atrial Fibrillation 04/2022 - 08/2008
4	Diabetes Mellitus 11/2019 - 05/2003
4	Cerebral Infarction 01/2019 - 01/2013
4	Hemorrhagic Stroke 09/2017 - 06/2006
4	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 10/2015 - 07/2005
4	Thrombosis (Thrombus) 10/2015 - 03/2007
4	Ischemia 12/2011 - 02/2003
3	Atherosclerosis 12/2020 - 12/2007
3	Hematoma 01/2018 - 03/2009
3	Arterial Occlusive Diseases (Arterial Occlusive Disease) 01/2016 - 05/2010
3	Neoplasms (Cancer) 09/2013 - 11/2002
3	Brain Injuries (Brain Injury) 12/2010 - 07/2005
3	Inflammation (Inflammations) 12/2010 - 07/2007
3	Hyperglycemia 09/2007 - 05/2003
2	Melanoma (Melanoma, Malignant) 01/2022 - 09/2013
2	Ganglion Cysts (Ganglion) 08/2019 - 01/2019
2	Hypertension (High Blood Pressure) 02/2014 - 01/2007
2	Cerebral Amyloid Angiopathy (Congophilic Angiopathy) 03/2012 - 01/2012
1	Cardiomyopathies (Cardiomyopathy) 04/2022
1	COVID-19 11/2020
1	Neurologic Manifestations (Neurological Manifestations) 11/2020
1	Embolism (Embolus) 11/2019
1	Nervous System Diseases (Neurological Disorders) 01/2019
1	Atrial Premature Complexes (Premature Atrial Contraction) 01/2019
1	Intracranial Thrombosis (Cerebral Thrombosis) 01/2019
1	Patent Foramen Ovale 01/2019
1	Vascular Diseases (Vascular Disease) 01/2018
1	Brain Infarction 09/2017

Drug/Important Bio-Agent (IBA)

50	Tissue Plasminogen Activator (Alteplase)FDA Link 10/2022 - 06/2002
20	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2022 - 12/2015
17	TicagrelorIBA 01/2022 - 12/2015
7	Biomarkers (Surrogate Marker)IBA 04/2022 - 08/2008
7	Matrix Metalloproteinases (MMPs)IBA 03/2012 - 02/2003
6	Proteins (Proteins, Gene)FDA Link 04/2022 - 07/2003
6	Glucose (Dextrose)FDA LinkGeneric 01/2019 - 05/2003
5	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 11/2019 - 03/2007
4	Cytidine Triphosphate (CTP)IBA 12/2022 - 01/2017
4	Matrix Metalloproteinase 9 (Gelatinase B)IBA 06/2006 - 02/2003
3	EnzymesIBA 12/2022 - 04/2003
3	Thrombin FDA Link 01/2022 - 04/2003
3	C-Reactive ProteinIBA 05/2008 - 10/2003
2	AnticoagulantsIBA 11/2019 - 11/2017
2	RivaroxabanIBA 11/2019 - 01/2019
2	Vitamin K FDA Link 11/2019 - 11/2015
2	salicylhydroxamic acid (SHAM)IBA 08/2019 - 01/2019
2	boldenone undecylenate (Equipoise)IBA 01/2019 - 12/2010
2	Hemostatics (Antihemorrhagics)IBA 02/2016 - 09/2012
2	UbiquitinIBA 02/2012 - 06/2008
2	Ligases (Synthetase)IBA 02/2012 - 12/2010
2	cytidylyl-(3'-5')-cytidine (CpC)IBA 01/2012 - 12/2011
2	danaparoid (Orgaran)FDA Link 12/2007 - 02/2004
2	Plasminogen Activator Inhibitor 1IBA 09/2004 - 06/2004
2	ImmunosorbentsIBA 07/2003 - 04/2003
1	Carboxypeptidase B2 (Thrombin Activatable Fibrinolysis Inhibitor)IBA 12/2022
1	Antifibrinolytic Agents (Antifibrinolytics)IBA 12/2022
1	CreatinineIBA 01/2022
1	Dabigatran FDA Link 01/2022
1	ORALIT (ORS)IBA 12/2021
1	pro-brain natriuretic peptide (1-76)IBA 10/2021
1	Neuroprotective AgentsIBA 01/2021
1	Clopidogrel (Plavix)FDA Link 01/2020
1	Factor Xa (Coagulation Factor Xa)IBA 11/2019
1	BenzodiazepinesIBA 01/2019
1	Contraceptive Agents (Contraceptives)IBA 01/2019
1	prothrombin complex concentrates (PPSB)IBA 01/2017
1	Indicators and Reagents (Reagents)IBA 01/2017
1	Factor VII (Proconvertin)IBA 01/2016
1	AntigensIBA 01/2016
1	Peptide Hydrolases (Proteases)FDA Link 01/2016
1	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 12/2015
1	Warfarin (Coumadin)FDA LinkGeneric 11/2015

Therapy/Procedure

47	Therapeutics 01/2021 - 01/2003
21	Thrombectomy 12/2022 - 01/2014
10	Time-to-Treatment 09/2014 - 09/2004
7	Thrombolytic Therapy 01/2019 - 07/2005
5	Endovascular Procedures 10/2015 - 01/2013
4	Aftercare (After-Treatment) 05/2017 - 01/2007
3	Stents 01/2021 - 11/2006
2	Contraindications 08/2019 - 01/2014
2	Punctures 03/2018 - 05/2013
2	Length of Stay 05/2017 - 05/2015
2	Secondary Prevention 09/2011 - 08/2008
2	Microbubbles 10/2008 - 02/2006
1	Artificial Respiration (Mechanical Ventilation) 11/2020
1	Injections 01/2019
1	Patient Transfer (Patient Dumping) 01/2019
1	Decompression 01/2018
1	Off-Label Use 11/2017
1	Embolectomy 06/2015